Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains

Digestive Diseases and Sciences

Volumn 49, Issue 2, 2004, Pages 300-303

  Kuwahara, Reiichiro ^a   Kumashiro, Ryukichi ^a   Inoue, Hiroto ^a   Tanabe, Ryo ^a   Tanaka, Eisuke ^a   Hino, Teruko ^a   Ide, Tatsuya ^a   Koga, Yuriko ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adefovir dipivoxil; Drug resistance; Hepatic failure; Hepatitis B virus; Lamivudine; YMDD motif

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; FUROSEMIDE; GLYCYRRHIZIC ACID; LAMIVUDINE; SPIRONOLACTONE; STONG NEO MINOPHAGEN; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; LIVER FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER FAILURE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETREATMENT; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 1642327085     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000017455.39171.56     Document Type: Article

References (27)

1. Lee WM: Hepatitis B infection. N Engl J Med 337:1733-1745, 1997
2. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312-323, 1993
3. Lok AS, Chung HT, Liu VW, Ma OC: Long-term follow-up of chronic hepatitis B patients treated with Interferon alfa. Gastroenterology 105:1833-1838, 1993
4. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971-975, 1999
5. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661, 1995
6. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68, 1998
7. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263, 1999
8. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713, 1996
9. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NW, Tyrrell DL: Mutation in the HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717, 1996
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, for the Adefovir Dipivoxil 438 Study Group: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348:800-807, 2003
11. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn M, Xiong S, Fry J, Brosgart CL, for the Adefovir Dipivoxil 437 Study Group: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808-816, 2003
12. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, Omata M: Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 103:1635-1640, 1999
13. Xiong S, Yang H, Westland CE, Delaney WE IV, Colledge D, Bartholomeusz A, Thibault V, Benhamou Y, Angus P, Wulfsohn M, Gibbs CS, Fry J, Brosgart CL, Locarnini S: Resistance surveillance of chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). J Hepatol 38(Suppl 2):182 (628), 2003
14. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297, 2003
15. Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S: Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 37:310-314, 1999
16. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN: On behalf of the Asia Hedpatitis Lamivudine Study Group: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532, 2001
17. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP: Fatal hepatic failure after the emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenteol 27:366-369, 2002
18. Bruno R, Sacchi P, Filice C, Filice G: Acute liver failure during lamivudine treatment in a hepatitis B cirrhotic patient. Am J Gastroenterol 95:265, 2001
19. Mutimer D, Pillay D, Cook P, Ratcliffe D, O'Donnell K, Dowling D, Shaw J, Elias E, Cane PA: Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infct Dis 181:713-716, 2000
20. Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Wellwe IV: A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 6:387-395, 1999
21. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutant. Hepatology 32:129-134, 2000
22. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 46:562-568, 2000
23. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amorouso A, Panella C, Francavilla A: Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 35:805-810, 2001
24. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, Loria A, Poupon R: Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: result of a pilot study. Hepatology 34:573-577, 2001
25. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burkhardt E, Schoonhoven R, Brenner DA, Fried MW: Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 35:749-755, 2001
26. Leung N. Liver disease-significant improvement with lamivudine. J Med Virol 61:380-385, 2000
27. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saith S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30:743-748, 1999